| Name | Title | Contact Details |
|---|
Modern Meadow was founded on the belief that customers should not have to choose between performance and sustainability. Additionally, we believe that people should not have to choose between a career that helps them achieve their personal goals and a career with purpose. Achieving both personal and professional goals with purpose is possible at Modern Meadow, and we invite qualified professionals to apply for positions of interest. At the intersection of biotechnology and material science, Modern Meadow designs materials solutions for the way we want the world to perform. We are pioneers of biofabrication, building with biology. This enbables us to harness unique properties of proteins to move the world away from petrochemical and animal-derived inputs, leading a shift to the bioeconomy. Modern Meadow Biofabricated Materials offer the world a new way forward. By introducing a more effective, more responsible, and readily available supply, we are shifting demand away from extractive practices and toward a sustainable bioeconomy. Our team is engaged in exciting work to enable us all to move beyond sustainability to real world impact. Our philosophy and sustainability principles help us stay focused on the most critical environmental issues and challenge us to design our products and systems in the most sustainable manner. But we cannot build a bioeconomy alone. We are partnering with companies, developing bio-based supply chains, and speaking with businesses looking to design for sustainability from the start. Together we can create new coalitions to build out the environmentally conscious alternatives our planet desperately needs.
An #AG biotech company focused on providing natural, science-based biological solutions for high-value crops. CSE: MGRO | OTCQB: MGROF | FRA: 0C0
AnGes Inc is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TYME, Inc. is a pharmaceutical company focused on creating medicines that specialize in using the body’s immune system to treat diseases. The body has the ability to fight off major diseases and heal itself. Tyme is researching a mechanism that it believes may work alongside the body’s immune system to fight Stage IV Metastatic Cancer. Tyme hopes to provide a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers (breast, lung, prostrate, gastric, esophageal and pancreatic cancers) responsible for 62% of the annual cancer deaths in the United States. The SM-88, Tyme’s proprietary compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. SM-88 is designed to penetrate the living cancer cells and introduce multiple mechanisms to kill the cell. Inducing transfer of electrons in the cancer cells may allow catalyzed external free radicals to react and stress the cell. SM-88 is a combination of low dose agents used for non-cancer treatment.
Caladrius is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of cell therapies designed to reverse disease and/or promote the regeneration of damaged tissue. The Company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company`s platform technology leverages these cells to enable the body`s natural repair mechanisms using formulations unique to each medical indication.